Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results